1.重庆医科大学附属第一医院中西医结合科,重庆 400016
2.北京中医药大学东直门医院血液肿瘤科,北京 100700
吴朝旭,男,27岁,硕士研究生,住院医师。研究方向:中西医结合防治恶性肿瘤及风湿免疫疾病。
董青,E-mail:dr_dongqing@126.com
扫 描 看 全 文
吴朝旭,侯丽,李潇,等.接受二线及后续治疗的晚期胃癌患者中医、西医临床特征分析[J].北京中医药,2023,42(3):333-337.
WU Chao-xu,HOU Li,LI Xiao,et al.Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(03):333-337.
吴朝旭,侯丽,李潇,等.接受二线及后续治疗的晚期胃癌患者中医、西医临床特征分析[J].北京中医药,2023,42(3):333-337. DOI: 10.16025/j.1674-1307.2023.03.027.
WU Chao-xu,HOU Li,LI Xiao,et al.Analysis of clinical characteristics of Chinese and western medicine inpatients with advanced gastric cancer receiving second-line and follow-up treatment[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(03):333-337. DOI: 10.16025/j.1674-1307.2023.03.027.
目的,2,基于45例接受二线及后续治疗的晚期胃癌患者的临床资料,探讨该类患者的中医、西医临床特征。,方法,2,对符合纳入标准的晚期胃癌患者,根据治疗方式分为一线治疗、二线及后续治疗2组,通过组间比较和文献研究归纳总结二线及后续治疗患者的中西医临床特征。,结果,2,45例接受二线及后续治疗的晚期胃癌患者男女比例约为3∶1,年龄(57.53±12.96)岁,体质指数(BMI)(21.51±3.89)kg/m,2,,血红蛋白(111.58±17.82)g/L,血清白蛋白(38.78±5.52)g/L,卡氏评分(KPS)集中于80分及以上,分化程度以低分化为主,原发灶以近端胃居多,远处转移以单脏器转移最为常见,与接受一线治疗患者比较,差异无统计学意义(,P,>,0.05);而腺癌占比95.56%,生存时间(440.80±177.42)d,明显高于接受一线治疗患者(,P,<,0.05)。中医证素中,病位证素的组合主要为脾、脾与肝、脾与肾,对应的病性组合分别为气虚证、痰湿证并见,气虚证、气滞证、痰湿证并见,气虚证、阴虚证并见。,结论,2,接受二线及后续治疗的晚期胃癌患者中医病位以脾、肝、肾为主,病性证素表现为虚实夹杂,临床宜合理安排扶正、祛邪等治法;与一线治疗患者相比,二线及后续治疗患者的西医特征表现为腺癌为主,印戒细胞癌极少。
Objective,2,To investigate the clinical characteristics of Chinese medicine and western medicine in 45 patients with advanced gastric cancer who received second-line and follow-up treatment based on the clinical data of these patients.,Methods,2,Patients with advanced gastric cancer who met the criteria for inclusion in the subject were divided into first-line treatment,second-line treatment and follow-up treatment according to the treatment methods. Through the comparison between groups and literature research, the clinical characteristics of Chinese and western medicine in patients with second-line and follow-up treatment were summarized.,Results,2,The male-to-female ratio of 45 patients with advanced gastric cancer who received second-line and subsequent treatments was about 3∶1, the average age was (57.53±12.96) years, the average BMI was (21.51±3.89) kg/m,2,,and the average hemoglobin was(111.58±17.82) g/L,serum albumin is(38.78±5.52) g/L, KPS score was concentrated at 80 points and above, and the degree of differentiation was mainly poorly differentiated. The primary tumor was mostly in the proximal stomach, and the distant metastasis was the most common single organ metastasis, there was no statistically significant difference compared to the first-line treatment patients(,P,>,0.05); while adenocarcinoma accounted for 95.56%, and the average survival time was(440.80±177.42) days, which was significantly higher than that of the first-line treatment patients(,P,<,0.05). The TCM evidence elements showed the characteristics of pathological combinations of spleen,liver and spleen,and spleen and kidney, and their corresponding pathological combinations were Qi deficiency with phlegm-dampness,Qi deficiency,Qi stagnation with phlegm-dampness, and Qi deficiency with Yin deficiency.,Conclusion,2,The pathological sites of 45 patients with advanced gastric cancer receiving second-line and follow-up treatment were mainly spleen, liver and kidney in TCM, and the pathological elements showed a combination of deficiency and excess, so it is advisable to use the treatment method of supporting the anti-pathogenic Qi and eliminating the pathogenic factors in a reasonable way. Compared with the first-line treatment patients, the western medicine characteristics of the second-line and follow-up treatment patients are mainly adenocarcinoma,but signet ring cell carcinoma is rare.
晚期胃癌二线治疗后续治疗临床特征
advanced gastric cancersecond-line treatmentfollow-up treatmentclinical characteristics
孙可欣, 郑荣寿, 张思维,等. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤,2019,28(1):1-11.
韩光锋. 晚期胃癌的内科治疗现状和进展[J]. 实用肿瘤杂志,2017,32(6):569-574.
TAKASHIMA A, BOKU N, KATO K, et al. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912[J]. Gastric Cancer, 2014,17(3):522-528.
HSU C, SHEN YC, CHENG CC, et al. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression[J]. Gastric Cancer, 2012,15(3):265-280.
FANOTTO V, CORDIO S, PASQUINI G, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world[J]. Gastric Cancer, 2017,20(5):825-833.
林洪生.恶性肿瘤中医诊疗指南[M].北京:人民卫生出版社,2014:313-314.
孟灵梅, 周丽雅, 李渊,等. 青年胃癌患者的临床特点分析[J]. 中国微创外科杂志,2017,17(1):46-50.
蔡铭泉,汤玮玮,安汉祥,等.肠内营养联合化疗治疗晚期胃癌的临床疗效研究[J].肠外与肠内营养,2017,24(4):205-208.
辛晓伟, 方玉, 龚丽青,等. 全程营养管理在晚期胃癌化疗病人中的应用[J]. 肠外与肠内营养,2019,26(4):193-197.
LEE JH, PARK B, JOO J, et al. Body mass index and mortality in patients with gastric cancer: a large cohort study[J]. Gastric Cancer, 2018,21(6):913-924.
刘昊, 田艳涛. 早期胃印戒细胞癌生物学行为的特殊性[J]. 中国医学前沿杂志(电子版),2019,11(2):5-8.
ZHANG C, LIU R, ZHANG WH, et al. Difference between signet ring cell gastric cancers and non-signet ring cell gastric cancers: a systematic review and meta-analysis[J]. Front Oncol, 2021,11:618477.
吴朝旭, 王寅, 栗枭杰,等. 基于SEER数据库的老年晚期胃癌预后因素分析[J]. 重庆医科大学学报,2021,46(10):1224-1227.
段连香, 郑坚, 赵爱光,等. 中医药辨证治疗对老年晚期胃癌预后影响的同期对照研究[J]. 肿瘤学杂志,2018,24(8):800-807.
禄颖.浅议《内经》之“神不使”[C]//中华中医药学会第十六次内经学术研讨会论文集.[出版者不详],2016:158-160.
吴朝旭.基于80例晚期胃癌患者的临床资料构建胃癌预后预测模型的研究[D].北京:北京中医药大学,2020.
杨涛, 李忠, 陈健,等. 基于数据挖掘和网络药理学的中药治疗胃癌作用机制研究[J]. 北京中医药,2020,39(10):1092-1098.
陈信义, 董青, 田劭丹,等. 恶性肿瘤中医药维持治疗临床价值与述评[J]. 北京中医药大学学报,2021,44(9):777-783.
移康军, 徐晓华, 李刘生,等. 基于“和”思想探讨恶性肿瘤的病机与治疗[J]. 北京中医药,2021,40(12):1352-1354.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构